FDA Approves New Breast Cancer Imaging System
The FDA has approved a fluorescence imaging system designed to detect residual breast cancer during surgery. The system aims to improve intraoperative detection of remaining cancer tissue, which could reduce re-excision rates and improve patient outcomes. For outpatient centers with surgical partnerships, this tech could be a key differentiator.
The newly approved system is the LumiSystem by Lumicell, which pairs the LUMISIGHT (pegulicianine) optical imaging agent with the Lumicell Direct Visualization System (DVS). This marks the first drug-device combination product approved in over a decade to undergo both of the FDA's most rigorous NDA and PMA review processes. The technology, developed through a collaboration including MIT, Duke University, and Massachusetts General Hospital, works by injecting the LUMISIGHT agent, which is then activated by enzymes overexpressed by tumors, causing cancerous tissue to fluoresce under the DVS handheld probe. Nationally, re-excision rates after an initial lumpectomy can range from 20% to as high as 40%, a significant variation often dependent on the surgeon and institution. These second surgeries increase the risk of complications, drive up healthcare costs, and can delay subsequent adjuvant therapies like radiation. The LumiSystem aims to directly address this by providing real-time, intraoperative assessment of the entire lumpectomy cavity, a notable advancement over traditional methods like frozen section analysis or specimen radiography, which can be time-consuming and less accurate. The approval comes as oncology services, including diagnostics and surgery, increasingly shift to outpatient settings. This migration is driven by technological advancements, patient preference for convenience, and payer pressure to reduce costs. For instance, the proportion of mastectomies performed at ambulatory surgery centers (ASCs) nearly doubled from 5.4% in early 2017 to 9.0% by the end of 2023. This trend makes advanced, efficient intraoperative technologies particularly valuable for freestanding centers competing for surgical partnerships. This site-of-care shift is also reshaping health system strategy, with many expanding their own freestanding imaging footprints through acquisitions, joint ventures, or new construction. Payers are actively steering patients toward these lower-cost outpatient facilities, a trend accelerated by site-neutral payment policies that aim to equalize reimbursement between hospital outpatient departments (HOPDs) and independent centers. As hospitals face declining reimbursement for imaging, acquiring or partnering with efficient outpatient centers becomes a key strategy to retain market share.
